The market for doxorubicin is anticipated to grow from US$ 1,390.64 million in 2022 to US$ 1,983.40 million in 2028, according to our most recent analysis, "Doxorubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis - By Drug Formulation, Distribution Channel, and Geography." Between 2022 and 2028, it is predicted to increase at a CAGR of 6.1%. The study identifies the major market growth drivers for doxorubicin as well as significant industry participants and their recent product advancements. The rising incidence of cancer and rising popularity of chemotherapy are major growth drivers for the industry. The expansion of the market is anticipated to be constrained during the forecast period by the potential negative effects of doxorubicin.

The global market for doxorubicin is divided into two categories based on drug formulation: doxorubicin injection and lyophilized powder. The lyophilized powder is anticipated to hold a greater market share in 2022. Additionally, from 2022 to 2028, the same market sector is predicted to see the greatest CAGR. The lyophilized powder market is expanding primarily due to its storage stability, which keeps the solid condition of the product at room temperature. Doxil is the first successful liposome-based medication for treating patients with ovarian cancer and AIDs-related Kaposi's sarcoma, and it was produced by Johnson and Johnson. Lyophilized powder can be used as a chemotherapy drug against various cancer types, including lymphoma, carcinoma, and various sarcomas.

Get Sample Copy of Report PDF: https://www.theinsightpartners.com/sample/TIPRE00011780/

Prior to the pandemic, the market for doxorubicin was expanding steadily due to the prevalence of routine cancer screening, evaluations, and treatments. The Covid-19 epidemic had a significant impact on the market. The initial COVID-19 wave interfered with the screenings, follow-ups, consultations, and therapies for oncological diseases. As a result, the region's health care infrastructure became overworked, making it difficult to provide medical care to all patients. Additionally, the majority of pharmaceutical, medical device, and research institutions were working on COVID-19 vaccines and associated goods. There were fewer consultations and cancer cases diagnosed as a result of the disorderly scenario that was created in the healthcare sector across the globe.

A few of the industry's top players are Accord Healthcare, Cipla Inc., Dr. Reddy, Cadila Pharmaceuticals, Meiji Seika Pharma Co., Janssen Pharmaceutical (Johnson and Johnson Services, Inc.), Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., and Baxter International Inc. Pfizer purchased Trillium Therapeutics Inc. in August 2021. The proposed acquisition strengthens Pfizer's oncology category leadership with next-generation, investigational immuno-therapeutics for haematological malignancies. Additionally, the pharmaceutical corporation Cipla said in June 2022 that it has agreed to pay Rs 25.90 crore for an additional share in the digital technology firm GoApptiv. By investing in GoApptiv in June 2020, the company saw growth and increased its channel reach into lower-class Indian towns. This funding will enable more patients by strengthening our cooperation with GoApptiv.

The research divides the doxorubicin market into the following segments:

The global market for doxorubicin is divided into two segments based on drug formulation: lyophilized powder and doxorubicin injection. The Lung Cancer, Sarcoma, Breast Cancer, Multiple Myeloma, Ovarian Cancer, Kidney Cancer, Leukemia, Liver Cancer, and Others categories make up the global doxorubicin market. Hospital pharmacies, retail pharmacies, and online pharmacies make up the three segments of the global doxorubicin market based on the distribution channel.

The US, Canada, and Mexico make up North America, followed by the UK, Germany, France, Italy, Spain, and the rest of Europe, followed by China, Japan, India, Australia, South Korea, and the rest of Asia Pacific, the Middle East & Africa, the UAE, Saudi Arabia, South Africa, and the rest of the Middle East & Africa, and finally South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Browse More Related Reports by the insight partners:

Liposomal Doxorubicin Market

https://www.theinsightpartners.com/reports/liposomal-doxorubicin-market

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876